

# Shilpa Medicare Limited



Innovating for  
affordable healthcare

**Manufacturers and Exporters of Bulk Drugs**

# 12-6-214/A1, Hyderabad Road,

RAICHUR - 584 135, Karnataka, India.

Phone : +91-8532 - 238704, Fax : +91-8532-238876

E-mail : [info@vbshilpa.com](mailto:info@vbshilpa.com) Website : [www.vbshilpa.com](http://www.vbshilpa.com)

CIN No. L85110KA1987PLC008739

Dated: 28<sup>th</sup> May, 2020.

Corporate Relationship Department,  
BST Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
**Mumbai-400 001**

National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
**MUMBAI-400 051**

Dear Sir/Madam,

**Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.  
Ref: Stock Code: NSE: SHILPAMED/BSE-530549**

\*\*\*\*\*

**Shilpa Medicare Launches Three Affordable Anticancer Drug in Indian Market  
within Four Months, the Third Launch "IBRUSHIL" is for the treatment of  
Leukemia**

After the Successful Launch of Lenvatinib "LENSHIL®" and Dasatinib "DASASHIL®" in India Market, Shilpa Medicare Limited today launches the Indian branded generic of Ibrutinib, an anti-cancer drug with a brand name **IBRUSHIL**.

IBRUSHIL is available in 140 mg capsules in packs of 30's capsules and 120's capsules.

IBRUSHIL is used to treat patients suffering from **Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphomas (MCL)** and other related cancers.

This new Leukemia drug is more effective and easier to use. IBRUSHIL attacks cancer cells without damaging normal cells, this causing fewer side effects. The drug is taken once daily, than the standard treatment that requires multiple injections by the patients.



# Shilpa Medicare Limited



Innovating for  
affordable healthcare

**Manufacturers and Exporters of Bulk Drugs**

# 12-6-214/A1, Hyderabad Road,  
RAICHUR - 584 135. Karnataka, India.

Phone : +91-8532 - 238704, Fax : +91-8532-238876

CIN No. L85110KA1987PLC008739

E-mail : info@vbshilpa.com Website : www.vbshilpa.com

Current, monthly therapy cost of innovator is approximately Rs. 4.36 Lacs, with the launch of IBRUSHIL monthly cost of treatment will be reduced drastically to Rs. 34920/- as monthly therapy cost.

According to the Vision of Shilpa Medicare Limited "Innovating for affordable healthcare" Cancer being a Chronic disease segment where patients need to take therapy for longer time, IBRUSHIL is launched to provide global quality Indian Brand with greater affordability to cancer patients says **Mr. Sundeip Bhatia, Business Head Formulations India.**

IBRUSHIL will revolutionise the treatment by ensuring to make therapy available for more Indian patients due to increased affordability.

IBRUSHIL (Ibrutinib 140 mg) capsules is being manufactured in the state-of-the-art US-FDA approved manufacturing facility. IBRUSHIL is the same product which was filed with US FDA thus Shilpa is bringing a quality product meeting the world class standards. In 2017, Shilpa filed an abbreviated new drug application (ANDA) with "first to file" status in the US and the same product is being now extended to India.

Today there are around 6,000-10,000 new patients in India who needs Ibrutinib which can be benefited by IBRUSHIL Capsules.

This is for your information and doing the needful.  
With Regards,

For SHILPA MEDICARE LIMITED

**V V KRISHNA CHAITANYA**  
COMPANY SECRETARY  
M.NO: 49415

